marijuana stocks news

Supreme Completes Operational Transition to Ontario

TORONTO, ONTARIO–(Marketwired – Feb 9, 2015) – Supreme Pharmaceuticals Inc. (the “Company”) (OTC PINK:SPRWF)(SL.V) is pleased to announce it has completed its operational transition from British Columbia to Ontario in order to focus resources on the Kincardine facility. The transition allows the Company to reduce operating overhead and focus efforts on obtaining required regulatory approvals at the Kincardine facility.

Further to the transition, Brayden Sutton will be resigning as Executive Vice-President, effective immediately, but will continue on with Company as a consultant for the near term to assist in completing the Company’s operational transition.

John Fowler, President of the Company stated, “Re-focusing our attention on Ontario is a big step in our journey to become a leading supplier of affordable medical marijuana in Canada. It allows us to concentrate on building our business around our flagship greenhouse facility. With our focus set squarely on Kincardine, I feel we are well positioned for future success.”

Currently, the Company continues to prepare for its post-license operations by engaging with various health care providers, patient groups and wholesale partners. At present, no date has been set for the pre-license regulatory inspection.


This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Supreme Pharmaceuticals Inc.
Investor Relations
(604) 674-2191

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 |
Leave a Reply

Your email address will not be published.

You May Also Like

$THCZ Receives Trademark From US Patent Office

Totally Hemp Crazy’s Rocky Mountain High Energy Drink(R) Receives Trademark From US…

$GBLX Partners with Fuzhou Seechance Holding

GrowBLOX Sciences Partners with Fuzhou Seechance Holding for Production of its Proprietary…

Terra Tech Corp. (TRTC) Secures Permit to Manufacture Cannabis for the Adult Use Market at Reno, Nevada Facility

Terra Tech Secures Permit to Manufacture Cannabis for the Adult Use Market…

InMed Pharmaceuticals Inc. (IMLFF) Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D…